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The production of blood cells during steady-state and increased demand depends on the
regulation of hematopoietic stem cell (HSC) self-renewal and differentiation. Similarly, the
balance between self-renewal and differentiation of leukemia stem cells (LSCs) is crucial in
the pathogenesis of leukemia. Here, we document that the TNF receptor superfamily member
lymphotoxin-β receptor (LTβR) and its ligand LIGHT regulate quiescence and self-renewal of
murine and human HSCs and LSCs. Cell-autonomous LIGHT/LTβR signaling on HSCs
reduces cell cycling, promotes symmetric cell division and prevents primitive HSCs from
exhaustion in serial re-transplantation experiments and genotoxic stress. LTβR deficiency
reduces the numbers of LSCs and prolongs survival in a murine chronic myeloid leukemia
(CML) model. Similarly, LIGHT/LTβR signaling in human G-CSF mobilized HSCs and human
LSCs results in increased colony forming capacity in vitro. Thus, our results define LIGHT/
LTβR signaling as an important pathway in the regulation of the self-renewal of HSCs
and LSCs.
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Hematopoietic stem cells (HSCs) represent a small het-erogeneous and hierarchically organized populationwithin lineage negative (Lin−) cells1. The hierarchy of
HSCs is characterized by the progressive decrease of the self-
renewal capability from long-term-HSCs (LT-HSCs) over short-
term HSCs (ST-HSCs) to multipotent progenitors (MPPs). HSC
self-renewal and differentiation is regulated by cell-intrinsic
mechanisms such as transcription factors (SATB1, PU-1), cell
cycle regulators (CDKN1A, GFI-1), or transcriptional regulators
(MSI2)2–4. In addition, cell-extrinsic cues from bone marrow
(BM) niche cells regulate HSC activity, that is, niche cells secrete
stem cell factor (SCF), angiopoietin-1, and thrombopoietin5, and
express adhesion molecules such as vascular cell adhesion pro-
tein 1 (ref. 6). In addition, stromal cell-derived factor 1
(CXCL12) promotes the retention of HSCs in the BM and
contributes to quiescence7.
Importantly, HSCs are able to adapt rapidly to increased
demands triggered by infections, inflammation, chemother-
apeutic agents, or ionizing radiation with increased cell cycling
and the production of hematopoietic progenitors8. This demand-
adapted hematopoiesis is activated by immune effector cytokines
such as interferon-α, interferon-γ, and tumor necrosis factor-α
(TNF-α) and Toll-like receptors (TLRs) that sense conserved
microbial products9,10.
To ensure lifelong production of all hematopoietic lineages, not
only the cell division of HSC but also the cell division fate, for
example, differentiation, has to be tightly controlled11. Asym-
metric cell division, leading to a differentiated and a self-
replicable daughter cell, assures a constant stem cell pool and a
progressive increase of differentiated cells. Symmetric division
leads to two identical daughter cells and the expansion of the
stem cell pool or, in rare situations, to two identical more dif-
ferentiated cells12.
Leukemic stem cells (LSCs) are responsible for leukemia
initiation and propagation13. They share several characteristics
with HSCs, including quiescence, self-renewal, and the capacity to
undergo symmetric and asymmetric cell division. Importantly,
most of the molecular pathways regulating HSCs also control
LSCs14,15 In addition, we and others showed that the TNF
receptor (TNFR) family member CD27 regulates self-renewal and
differentiation of HSCs and LSCs16–19.
The lymphotoxin-β receptor (LTβR), another member of the
TNFR family, is expressed on epithelial, stromal, and myeloid
cells but not on lymphocytes. Lymphotoxins are cytokines that
guide the interaction of immune cells, mainly lymphocytes, with
the surrounding stromal cells20. Lymphotoxin-α (LTα) and LTβ
as heterotrimers (LTα1β2) and LIGHT are known ligands for
LTβR21. LTβR signaling is crucially involved in the development
and organization of lymphoid tissue21. Therefore, secondary
lymphoid tissue is absent in Lta, Ltb, and Ltbr-knockout mice but,
interestingly, not in Light-knockout mice22,23. Ligation of LTβR
leads to TNFR-associated factor 2 (TRAF2)-NIK-mediated acti-
vation of the classical and alternative nuclear factor-κB (NF-κB)
pathway and the transcription of genes involved in inflammation
and development24. Disruption of LTβR signaling results in
impaired protection to viral and bacterial infections25,26. In
addition, cancer cells may express LTβR and agonistic antibodies
to LTβR trigger cancer cell death and suppress tumor growth
in vivo27.
In this work, we document that LIGHT expressed by HSCs
induces quiescence and self-renewal by cell-autonomous ligation
of LTβR. Importantly, LIGHT expression is upregulated in HSCs
in response to increased demands of progenitors and differ-
entiated blood cells. LIGHT/LTβR signaling reduces cell cycling
of HSCs, promotes symmetric over asymmetric cell division, and,
thereby, maintains the pool of primitive HSCs. Although the
maintenance of primitive HSC is crucial to secure hematopoiesis
long-term, the accumulation of primitive LSCs and the lack of
differentiation promote disease progression in leukemia28.
Indeed, LIGHT/LTβR signaling maintains and expands the pool
of LSCs in a murine model of chronic myeloid leukemia (CML)
and promotes disease progression. Similarly, LIGHT/LTβR sig-
naling induces stemness in human CML stem/progenitor cells.
Importantly, LIGHT is upregulated in LSCs compared to normal
HSCs. This may allow selectively targeting LSCs and inducing
differentiation. Collectively, this study identifies the LIGHT/LTβR
pathway as a crucial regulator of self-renewal of HSCs and LSCs.
Results
LTβR regulates self-renewal of HSCs. First, we analyzed
the expression of LTβR on different murine hematopoietic
stem/progenitor cell (HSPC) subsets during homeostasis.
ImageStreamX MkII analysis of fluorescence-activated cell sorting
(FACS)-purified Lin−sca1+c-kit+ cells (LSKs) from BM revealed a
strong surface expression of LTβR (Fig. 1a). In addition, defined
LSK subpopulations such as LT-HSCs (CD150+CD48−
CD34−CD135−), ST-HSCs (CD150+CD48−CD34+CD135−),
MPPs (MPP1: CD150+CD48+CD34+CD135−; MPP2: CD150−
CD48+CD34+CD135−; MPP3: CD150−CD48+CD34+CD135+),
as well as common myeloid progenitors (CD34+FcγRII/III−c-kit+
sca1−), common lymphoid progenitors (CD127+c-kitintsca1−
Thy1.1−), granulocyte–macrophage progenitors (CD34+FcγRII/
III+c-kit+sca1−), and megakaryocyte-erythroid progenitors
(CD34−FcγRII/III−c-kit+sca1−)1,29,30, expressed LTβR as ana-
lyzed by FACS (Fig. 1b and Supplementary Fig. 1a). Furthermore,
differentiated myeloid cells in the BM and peripheral blood (PB)
expressed LTβR, whereas T- and B-lymphocytes only marginally
expressed LTβR (Supplementary Fig. 1b).
To analyze the functional relevance of LTβR expressed on
hematopoietic cells, we first compared hematopoiesis in naive BL/6
and Ltbr−/− mice. BL/6 and Ltbr−/− mice had similar numbers of
LSKs (LT-HSC, ST-HSC, and MPPs), lymphoid progenitors
(common lymphoid progenitors), and myeloid progenitors
(granulocyte–macrophage progenitors, common myeloid progeni-
tors, megakaryocyte-erythroid progenitors) in the BM (Fig. 1c–f).
In addition, BL/6 and Ltbr−/− LSKs had a comparable cell cycle
activity and apoptosis rate (Supplementary Fig. 1c, d). Moreover,
FACS-purified LSKs from BL/6 and Ltbr−/− mice formed similar
numbers of colonies in methylcellulose ex vivo (Fig. 1g). Since not
only HSCs but also early progenitor cells form colonies ex vivo in
methylcellulose31,32, we analyzed the self-renewal capacity of HSCs
in serial re-plating experiments33. Ltbr−/− LSKs lost the capacity to
form colonies in methylcellulose after the third and fourth re-
plating, indicating that LTβR signaling contributes to the self-
renewal of HSCs (Fig. 1g).
Since differences between BL/6 and Ltbr−/− HSCs only became
apparent in serial re-plating assays in vitro that require cell
expansion and differentiation, we determined the function of
LTβR on LSKs in vivo in a competitive repopulation experiment
(Fig. 1h). We first injected congenic Ltbr-proficient (Ly5.1+,
referred to as Ly5.1) LSKs and LTβR-deficient (Ly5.2+, referred
to as Ltbr−/−) LSKs into lethally irradiated Ly5.1/Ly5.2 recipient
mice. Importantly, injected LSKs homed to the BM independent
of LTβR expression (Supplementary Fig. 1e). However, Ltbr−/−
LSKs reconstituted recipient mice more efficiently than control
LSKs, resulting in >60% Ltbr−/− Lin− cells in the BM 16 weeks
post transplantation (Fig. 1i and Supplementary Fig. 1f). This was
also reflected by a significant higher fraction of all HSPC
subpopulations (Fig. 1j–n and Supplementary Fig. 1g–j) in the
BM and higher numbers of Ltbr−/− leukocytes in PB (Supple-
mentary Fig. 1k).
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To study the self-renewal capacity of HSCs, we performed serial
re-transplantations with equal numbers of FACS-purified Ltbr−/−
and Ly5.1 LSKs. This resulted in a comparable reconstitution of
HSPCs in the second transplantation (Fig. 1i–n and Supplemen-
tary Fig. 1f–j) and similar numbers of LTβR-competent and
LTβR-deficient leukocytes in blood (Supplementary Fig. 1l).
Importantly, Ltbr−/− LSKs lost the capacity to reconstitute
hematopoiesis in the third transplantation, resulting in only
~3% Ltbr−/− HSPCs in BM and differentiated leukocytes in blood
(Fig. 1i–n and Supplementary Fig. 1f–j, m). Taken together, these
Fig. 1 LTβR expressed by LSKs prevents exhaustion of HSCs. a Left: LTβR expression (red) on BL/6 and Ltbr−/− FACS-purified BM LSKs analyzed by
ImageStreamX MkII. Right: ImageStreamX MkII histogram of LTβR expression on Ltbr−/− LSKs (gray) vs. BL/6 LSKs (red). b Representative FACS
histograms of LTβR expression on BM LSK subsets and myeloid progenitor cells. Numbers in plots indicate the ratio MFI stain/isotype (n= 5 mice).
c–f Absolute numbers of LSKs (c), LT/ST-HSCs (d), MPPs (e), CLPs and myeloid progenitors (MEP, CMP, GMP) (f) in the BM of naive BL/6 (black, n= 6)
and Ltbr−/− (red, n= 6) mice. g Fold change in CFU of Ltbr−/− LSKs relative to BL/6 LSKs in serial re-platings in vitro (1st: n= 8 for BL/6 and 11 for
Ltbr−/−; 2nd: n= 8 for BL/6 and 11 for Ltbr−/−; 3rd: n= 6 for BL/6 and 8 for Ltbr−/−; 4th: n= 3 for BL/6 and 5 for Ltbr−/−, one out of two independent
experiments). h Schematic of mixed BM chimera and serial re-transplantation. i–n Percentages of Ly5.1 and Ltbr−/− Lin− cells (i) and LSK subsets (j–n),
n= 5 (1st), n= 4 (2nd), n= 3 (3rd), one out of two independent experiments is shown. Data are shown as mean ± SEM. Statistics: *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001 (two-tailed t test); g: 1st p= 0.05, 2nd p= 0.039; i: 1st p < 0.0001, 3rd p < 0.0001; j: 1st p= 0.0012, 3rd p= 0.0003; k: 3rd
p < 0.0001; l: 1st p < 0.0001, 3rd p < 0.0001; m: 1st p= 0.0004, 3rd p= 0.0001; n: 1st p < 0.0001, 3rd p < 0.0001.
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data indicate that LTβR signaling crucially contributes to self-
renewal of HSCs.
Cell-autonomous expression of LIGHT induces LTβR signaling
and self-renewal of HSCs. LTβR signaling can be induced by
ligation with LTα1β2 heterotrimers and LIGHT34. Therefore, we
analyzed messenger RNA (mRNA) expression of these ligands in
naive Ly5.1 LSKs and BM niche cells, such as osteoblasts, endo-
thelial cells (ECs), and mesenchymal stromal cells (MSCs). In
addition, FACS-purified Ly5.1 LSKs from chimeras 6 weeks post
transplantation were analyzed (Fig. 2a and Supplementary
Fig. 2a). Lta and Ltb mRNA was expressed at very low levels in
LSKs from both naive and chimeric mice. However, the mem-
branous form of Light was expressed in naive LSKs and its
expression was increased ~2.5-fold in Ly5.1 LSKs isolated from
chimeric mice (Fig. 2a). By contrast, LTβR ligands were only
expressed at low levels in BM niche cells, with the exception of
osteoblasts that showed higher Light expression (Supplementary
Fig. 2a). Interestingly, Ltbr mRNA expression in LSKs from
chimeric mice 6 weeks post transplantation was increased ~12-
fold when compared to naive LSKs (Fig. 2b).
The high expression of LIGHT on LSKs prompted us to
analyze its role in the maintenance and regulation of HSPCs.
Similar to our results in Ltbr−/− mice, the HSPC composition in
the BM of naive BL/6 and Light−/− mice was comparable
(Supplementary Fig. 2b–d). In addition, no differences were
found in cell cycle activity and apoptosis rate of LSKs in the
absence of Light (Supplementary Fig. 2e, f). To further elucidate
whether LIGHT-induced LTβR signaling regulates LSK colony
formation capacity in vitro, we performed a serial re-plating
experiment. In line with our findings obtained with Ltbr−/−
LSKs, colony formation capacities of Light−/− LSKs were
gradually lost in serial re-plating experiments in vitro (Fig. 2c).
These data suggest that LIGHT expressed by LSKs triggers
LTβR signaling and regulates colony formation in vitro. LTβR
expressed on LSKs may bind to LIGHT in trans (in which the
ligand is expressed on another cell) or in cis (the ligand is
expressed by the same cell as the receptor). To distinguish
between cis- and trans-signaling, we performed mixed colony
assays with FACS-purified green fluorescent protein (GFP)-
expressing LIGHT-proficient LSKs and LIGHT-deficient LSKs.
LIGHT provided by surrounding LSKs did not rescue the colony-
forming capacity of LIGHT-deficient LSKs in serial re-plating
experiments (Fig. 2d). This indicates that cell-autonomous
LIGHT/LTβR signaling maintains HSC self-renewal capacity.
To study the self-renewal capacity of Light−/− LSKs in vivo, we
performed competitive serial repopulation experiments (Fig. 2e).
Light−/− LSKs reconstituted primary recipient mice more
efficiently, resulting in a chimerism of ~70% of Lin− BM cells
and HSC subsets, as well as higher numbers of leukocytes in
blood (Fig. 2f–j and Supplementary Fig. 2g–j). However, Light−/−
LSKs subsequently lost the capacity to reconstitute hematopoiesis
in serial transplantations, resulting in <10% Light−/− HSPCs and
differentiated leukocytes in the fourth transplantation (Fig. 2f–j
and Supplementary Fig. 2g–k). Similarly to the in vitro coculture
experiments with LIGHT-proficient and LIGHT-deficient LSKs,
LIGHT expressed by surrounding hematopoietic cells did not
rescue the defect in self-renewal of LIGHT-deficient LSKs in vivo.
These experiments suggest that cell-autonomous (cis) LIGHT/
LTβR signaling maintains LSK self-renewal. However, Light
mRNA was also expressed on osteoblasts (Supplementary Fig. 2a).
Therefore, we analyzed whether LIGHT-expressing cells of the
BM microenvironment contribute to LTβR signaling in HSCs by
transplanting Ly5.1 or Light−/− (Ly5.2+) LSKs into Ly5.1/Ly5.2
or Ly5.1/Light−/− recipients (Fig. 2k). This experiment revealed
that LIGHT deficiency on host cells did not alter the reconstitu-
tion potential and self-renewal capacity of Ly5.1 HSPCs in serial
re-transplantation experiments in vivo. By contrast, Light−/−
LSKs reconstituted hematopoiesis more efficiently in first
transplantation and then gradually lost the capacity to recon-
stitute hematopoiesis in second, third, and fourth transplanta-
tions, independently of the expression of LIGHT in recipient mice
(Fig. 2l–o and Supplementary Fig. 2l–o). This indicates that
LIGHT ligates LTβR in a cell-autonomous fashion in vivo leading
to LT-HSC self-renewal.
Loss of LTβR increases cell cycle-related gene expression while
reducing the expression of genes associated with stemness. In
order to study the molecular mechanisms of LTβR-mediated HSC
regulation, we performed a transcriptomic analysis of Ly5.1 and
Ltbr−/− LT/ST-HSCs from chimeric mice using RNA-sequencing
(RNA-seq) analysis (Fig. 3a). Ly5.1 or Ltbr−/− LT/ST-HSCs from
different chimeras had similar gene expression profiles and
therefore clustered together in a principal component analysis
(PCA) (Fig. 3b). Two hundred and twenty-seven genes were
differentially expressed between Ly5.1 and Ltbr−/− LT/ST-HSCs
6 weeks post transplantation (Fig. 3c and Supplementary data 1).
Gene set enrichment analysis (GSEA) revealed a downregulation
of stemness- and apoptosis-related gene signatures, but an
upregulation of stem cell proliferation, differentiation and cell
cycling genes in Ltbr−/− vs. control LT/ST-HSCs (Fig. 3e). Gene
expression analysis by quantitative reverse transcription PCR
revealed an upregulation of genes involved in the cell cycle reg-
ulation and differentiation, such as Myc, Ccnd1, Cdk4, and Numb
in the absence of LTβR signaling. By contrast, stemness-related
genes, such as those encoding for RNA-binding protein Musashi
2 (Msi2), Kit, and growth factor independent 1 transcriptional
repressor (Gfi1), were significantly downregulated (Supplemen-
tary Fig. 3a).
LIGHT-induced LTβR signaling promotes apoptosis35. Simi-
larly, Ltbr−/− LT/ST-HSCs and LSKs expressed proapoptotic
genes at lower levels and antiapoptotic genes at higher levels
compared to Ly5.1 controls (Supplementary Fig. 3a).
In silico network and canonical pathway analysis from LSKs
confirmed that LTβR directly and indirectly regulates cell cycle,
proliferation, apoptosis, and stemness-related pathways (e.g. Wnt,
NF-κB, regulators of HSC activity, and hematopoiesis) (Supple-
mentary Fig. 3b). Interestingly, GSEA of Ltbr−/− LT/ST-HSCs for
signatures of both NF-κB pathways revealed significant alteration
in the canonical NF-κB pathway but not in the signature of the
noncanonical pathway (Fig. 3e). Correspondingly, Traf2 mRNA
expression was lower in Ltbr−/− vs. Ly5.1 LSKs (Supplementary
Fig. 4a, b).
Many of the TNFR ligands including LIGHT have been shown
to provide reverse signaling36. LIGHT reverse signaling leads to
the activation of MAPK/ERK and PI3K-AKT pathways37. GSEA
revealed no differences in the signatures for MAPK, MAPK/ERK,
or PI3K-AKT signaling (Supplementary Fig. 4c). Collectively, our
data suggest that LTβR regulates HSC stemness in stress-induced
hematopoiesis through activation of the canonical NF-κB
pathway.
LTβR regulates HSC activity and promotes symmetric cell
division. We next sought to functionally analyze the mechanisms
by which LTβR signaling regulates HSC function. To this end, we
analyzed cell viability, cell cycle activity, and cell division of Ly5.1
and Ltbr−/− HSCs in chimeric mice. Fewer Ltbr−/− HSCs but not
MPPs underwent apoptosis when compared to controls 6 weeks
after transplantation (Fig. 4a). However, this difference dis-
appeared 12 weeks after transplantation (Fig. 4b).
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The reconstitution of hematopoiesis in secondary recipient
mice requires that LT-HSCs enter the active cell cycle and expand
in numbers by approximately a factor of 10 (refs 38,39). To
examine cell cycle activity, we FACS-purified Ly5.1 and Ltbr−/−
LSKs and stained the LSK subsets with Ki67 and 4′,6-diamidino-
2-phenylindole (DAPI). LTβR deficiency did not affect cell cycle
activity in total LSKs. However, analysis of LSK subpopulations
revealed that quiescent (G0) LT-HSCs but not ST-HSCs and
MPPs were reduced in the absence of LTβR signaling (Fig. 4c, d).
This indicates that LTβR signaling supports quiescence in the
most primitive HSC subset, the LT-HSCs. Similarly, Light−/−
LT-HSCs showed reduced quiescence in a similar experimental
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Fig. 2 LIGHT expressed by LSKs prevents exhaustion of HSCs. a Relative mRNA expression of Light (red), Lta (black), and Ltb (gray) by FACS-purified
LSKs from naive mice (n= 3) and 1st chimeras 6 weeks post transplantation (n= 4 mice, two were pooled for the analysis). b Relative mRNA expression of
Ltbr by FACS-purified LSKs from naive mice (n= 3 mice) and 1st chimeras 6 weeks after transplantation (n= 4 mice, two were pooled for the analysis).
c Fold change in colony formation of Light−/− BM LSKs (red) relative to BL/6 BM LSKs (black) in serial re-platings (n= 6). One out of two independent
experiments is shown. d Percentage of CFU from Light−/− (gray) or BL/6- GFP LSKs (black) in mixed colony-forming assays. The frequency of GFP+
(BL/6) vs. GFP− (Light−/−) colonies is shown. Data are pooled from two independent experiments and presented as mean ± SEM. e Experimental scheme
for serial transplantations of Light−/− Ly5.1 mixed BM chimeras. f–j Chimerism (red: Light−/−; black: Ly5.1) in percentages of donor Lin− cells (f), LT-HSCs
(g), ST-HSCs (h), MPP1 (i), MPP2/3 (Lin−c-kit+sca1+CD150−CD48+) (j). Data are shown as mean ± SEM of n= 7 (1st), n= 6 (2nd), n= 3 (3rd, 4th)
mice. k Experimental scheme of the serial transplantation of Ly5.1 and Light−/− LSKs (1:1) into lethally irradiated Ly5.1/Ly5.2 and congenic Ly5.1/Light−/−
recipients. l–o Percentages of donor Lin− cells in Ly5.1/Ly5.2 (l) and Ly5.1/Light−/− recipients (m) and LSKs in Ly5.1/Ly5.2 (n), and Ly5.1/Light−/−
recipients (o). Data are shown as mean ± SEM, Ly5.1/Ly5.2 recipients: n= 7 (1st), n= 5 (2nd), n= 3 (3rd); n= 3 (4th) Ly5.1/Light−/− recipients:
n= 5 (1st), n= 5 (2nd), n= 3 (3rd), n= 3 (4th). One out of two independent experiments is shown, Statistics: *P < 0.05, **P < 0.01, ***P < 0.001,
and ****P < 0.0001 (two-tailed t test), a: p= 0.005; b: p < 0.0001; c: p= 0.0014; d: p= 0.014, f: 1st p < 0.0001, 4th p < 0.0001; g: 1st p= 0.0289,
4th p < 0.0001; h: 1st p < 0.0001, 4th p < 0.0001; i: 1st p < 0.0001, 4th p < 0.0001; j: p < 0.0001, 4th p < 0.0001; l: 1st p < 0.0001, 4th p= 0.043;
m: 1st p= 0.0004, 4th p < 0.0001; n: 1st p < 0.0001, 3rd p= 0.0005; o: p= 0.0005. .
Fig. 3 Loss of LTβR leads to a higher expression of genes related to cell cycling and survival while reducing the expression of genes defining stemness.
a Experimental setting. FACS-purified Ltbr−/− and Ly5.1 LT/ST-HSCS from chimeras 6 weeks after primary transplantation (n= 6, pooled to three
biological replicates) were used for RNA-seq analysis. b PCA with samples plotted using the 1st two principal components. c Volcano plot of differentially
regulated genes. d Hierarchical clustering. e Gene set enrichment analysis (GSEA, pathcards.genecards.org) .
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Fig. 4 Ltbr deficiency induces proliferation and differentiation of HSCs. a, b Percentages of Annexin-V+ HSCs and MPPs 6 (a) and 12 (b) weeks after 1st
transplantation, black: Ly5.1, red: Ltbr−/−. One out of two independent experiments is shown, for a: n= 3, for b: n= 6 mice c Representative dot plot of the
cell cycle analysis as determined by Ki67 and DAPI staining of Ly5.1 and Ltbr−/− BM LSKs and LT-HSCs 12 weeks after primary transplantation. Numbers in
plots are shown as percentages of cells in each cell cycle phase, G0 in gray, G1 in red, and G2–M–S in black. d Frequency of Ly5.1 and Ltbr−/− LSKs, LT-
HSCs, ST-HSCs and total MPPs in different cell cycle phases 12 weeks post transplantation. Data are representative for two independent experiments, n=
3. e Frequency of Ly5.1 and Light−/− LSKs, LT-HSCs, ST-HSCs, and total MPPs (CD48+) in different cell cycle status 12 weeks post transplantation. LSKs
were isolated from two to three chimeric mice and pooled for the analysis. Pooled data from two independent experiments are shown. f Representative
picture of Numb distribution in dividing Ly5.1 and Ltbr−/− FACS-purified LT/ST-HSCs 10–12 weeks after transplantation. DAPI in violet, α-tubulin in green,
and Numb in red. Plane cell division (yellow line) was assigned based on α-tubulin and the cleavage furrow. Left: Quantification of Ly5.1 (92 cells from n=
3, pooled for the analysis) and Ltbr−/− LSKs (135 cells from n= 4, pooled for the analysis) in SD (black) or AD (red). Right: Quantification of Ly5.1 (45 cells
from n= 9, pooled for analysis) and Ltbr−/− LT/ST-HSCs (28 cells from n= 9, pooled for analysis) in symmetric cell division (SD) or asymmetric cell
division (AD). Cells were analyzed by ImageStreamX MkII. Nuclei were stained with DAPI. Data are shown as mean ± SEM. Statistics: *P < 0.05, **P < 0.01
(two-tailed t test), a: p= 0.028; f (AD, SD right panel): p= 0.033.
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setup (Fig. 4e). Taken together, these experiments indicate that
LIGHT/LTβR signaling maintains quiescence in primitive HSCs.
Re-entry of HSCs into cell cycle comprises the control between
asymmetric and symmetric division that governs differentiation
and maintenance of the stem cell pool6,12. To assess whether
LTβR signaling regulates the cell fate decision of HSPCs, we
quantified asymmetric and symmetric cell divisions of Ly5.1 and
Ltbr−/− LSKs by analyzing the cell fate determinant Numb, a
protein known to be distributed either symmetrically or
asymmetrically in daughter cells during the division of stem/
progenitor cells. A higher Numb expression is associated with
differentiation2,40,41. The expression of Numb showed a trend
towards higher levels in Ltbr−/− HSCs compared to Ly5.1 HSCs
(Supplementary Fig. 5). The absence of LTβR signaling in FACS-
purified LSKs and LT/ST-HSCs promoted asymmetric over
symmetric cell division (Fig. 4f). Symmetric cell division can
theoretically lead to two stem cells (self-renewal) or to two
differentiated daughter cells (commitment)28. Overall, this
indicates that LIGHT/LTβR signaling in primitive HSCs main-
tains self-renewal by regulating cell proliferation and asymmetric
vs. symmetric cell division.
LTβR regulates HSC function after genotoxic stress. Genotoxic
drugs or irradiation lead to damage and eradication of hemato-
poietic cells and results in the activation of a demand-adapted
hematopoiesis in order to replenish the hematopoietic system. To
test hematopoietic reconstitution after genotoxic stress, we treated
BL/6 and Ltbr−/− mice with fluorouracil (5-FU)42. Since treat-
ment with 5-FU leads to downregulation of c-kit43, LSKs and all
HSCs subsets were gated within the Lin−sca-1+ fraction (Sup-
plementary Fig. 6a). 5-FU treatment resulted in increased Ltbr
and Light mRNA and LTβR protein expression in LSKs
(Fig. 5a–c). Interestingly, total BM cellularity was significantly
higher in Ltbr−/− compared to BL/6 mice 8 days after 5-FU
treatment (Fig. 5d). In addition, the number of LT-HSCs was
significantly increased in Ltbr−/− compared to BL/6 mice,
whereas the number of ST-HSCs and MPPs remained unchanged
(Fig. 5e). In accordance with the reduced apoptosis rate of
Ltbr−/− HSCs in chimeric mice (Fig. 4a), significantly fewer
Ltbr−/− HSCs and CD150+/CD48+ MPPs stained Annexin-V+
compared to controls (Supplementary Fig. 6b). In addition, sig-
nificantly fewer Ltbr−/− LSKs were in the G0 phase of the cell
cycle compared to BL/6 LSKs (Fig. 5f). Moreover, Ltbr deficiency
resulted in an increase in asymmetric over symmetric cell division
(Fig.5g). LSKs from Ltbr−/− mice initially formed significantly
more colonies 8 days after 5-FU treatment. Importantly, HSC and
progenitors form colonies in the first plating. However, colony
formation was consecutively lost in serial re-platings, suggesting a
loss of HSCs with self-renewal capacity (Fig. 5h).
The phosphorylation and degradation of IκBα is a key process
resulting in NF-κB activation44. IκBα was expressed at higher
levels in naive and in 5-FU-treated Ltbr−/− LT/ST-HSCs
(Supplementary Fig. 6d, f). Importantly, the pIκBα/IκBα ratio
was similar in naive Ltbr−/− LT/ST-HSCs but significantly
reduced after 5-FU treatment when compared to control HSCs
(Fig. 5i, j). This indicates that, in response to 5-FU treatment,
LTβR signals via the canonical NF-κB pathway.
Since LTα1β2 is an additional ligand for LTβR and LIGHT also
ligates herpesvirus entry mediator (HVEM), we analyzed a
possible role of additional ligands/receptor in Light and Ltbr
double knockout (KO) mice. Light−/−/Ltbr−/− LSKs had a
similar phenotype in colony formation compared to single KO
LSKs, suggesting that LIGHT/LTβR acts as a ligand/receptor pair
and excluding a major role of other ligands/receptors (Supple-
mentary Fig. 6g, h).
To study the number and function of HSCs after 5-FU
treatment in vivo, we transplanted BM cells from 5-FU-treated
Ly5.1 and Ltbr−/− donors into lethally irradiated Ly5.1/Ly5.2
mice (Fig. 5k). Ltbr−/− donor BM cells reconstituted recipient
mice less efficiently than control BM cells, resulting in a
significantly reduced frequency of Lin− cells and HSPCs (Fig. 5l).
These findings suggest that the frequency of HSCs capable of
reconstituting recipient mice is significantly lower in 5-FU-
treated Ltbr−/− mice than in controls. Together, these data
indicate that LIGHT/LTβR signaling reduces cell proliferation
and asymmetric cell division and thereby maintains the pool of
HSCs in response to genotoxic stress.
LIGHT/LTβR signaling in LSCs promotes CML development.
So far, our data indicated that LTβR signaling regulates HSC cell
cycling and self-renewal. Since self-renewal and regulation of cell
fate in LSCs is crucial for the development of the disease, we next
studied LTβR signaling in a murine CML model45 CML-like
disease was induced by injection of BCR-ABL1-GFP-transduced
BL/6 or Ltbr−/− LSKs into nonirradiated BL/6 recipients (Fig. 6a).
In this model, LSCs are characterized as GFP+LSKs and LSC
subsets are defined in analogy to normal HSC subpopulations18
(Supplementary Fig. 7a).
LSCs expressed Ltbr mRNA at significantly higher levels than
normal LSKs (Fig. 6b). FACS analysis revealed that LTβR was
expressed on LSCs and leukemia progenitors with the highest
expression on LT-LSCs (Fig. 6c and Supplementary Fig. 7b–d). In
addition, LSCs expressed Light at higher levels than normal LSKs
(Fig. 6d). Ltbr−/− CML progressed significantly slower than BL/6
CML with reduced leukemia granulocytes in PB leading to a
prolonged survival (Fig. 6e, f). In addition, spleen weights of
Ltbr−/− CML mice were significantly reduced compared to BL/6
CML mice 19 days post transplantation, indicating a lower
leukemia burden (Fig. 6g). Importantly, significantly fewer LSCs
(LT- and ST-LSCs) and MPPs were found in the BM of Ltbr−/−
compared to BL/6 CML mice 19 days after transplantation
(Fig. 6h–j).
In order to functionally analyze the role of LTβR signaling in
LSCs, we transplanted either whole BM or FACS-purified LSCs
from primary BL/6 and Ltbr−/− CML mice into nonirradiated
BL/6 recipients (Fig. 6k). Recipients of Ltbr−/− CML BM (Fig. 6l)
or LSCs (Fig. 6m) survived significantly longer than recipients of
BL/6 BM or LSCs, respectively. This indicates that Ltbr−/− CML
harbors fewer LSCs and that the phenotypically characterized
Ltbr−/− LSCs are functionally impaired.
Lack of LTβR on LSCs increased cell cycle activity with an ~2-
fold decrease of LT-LSCs in G0 phase compared to BL/6 LT-LSCs
(14.7 ± 10.2 vs. 33.4 ± 11.6). By contrast, cell cycle activity of
ST-LSCs or MPPs did not depend on LTβR signaling (Fig. 6n).
Moreover, the analysis of the distribution of Numb in dividing
LSCs in telophase revealed an increased number of Ltbr−/− LSCs
in asymmetric over symmetric cell division (Fig. 6o). Moreover,
Numb expression is higher in Ltbr−/− LSCs compared to BL6
LSCs (Supplementary Fig. 7e).
Similarly, CML induced by Light−/− BCR-ABL1-GFP LSKs
(Light−/− CML) progressed significantly slower than BL/6 CML
with reduced numbers of leukemia granulocytes in PB and
significantly reduced spleen weights 18 days post transplantation
(Fig. 6p, q). In addition, significantly fewer LSCs (LT- and ST-
LSCs) and MPPs were found in the BM of Light−/− compared to
BL/6 CML mice 18 days post transplantation (Fig. 6r–t).
Supplementation of recombinant LIGHT in the colony-forming
assay did not rescue the KO phenotype (Supplementary Fig. 7f).
This finding is in agreement with the documented role of cell-
autonomous LIGHT/LTβR (cis) signaling. These data indicate
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that LIGHT/LTβR signaling regulates cell division and cell fate in
LSCs and promotes disease progression.
LTβR signaling regulates stemness in human CD34+ HSPCs.
LTBR and LIGHT are expressed by human CD34+ BM cells on
the mRNA level (GEO: GSE32719)46 (Fig. 7a). Next, we silenced
LTβR expression in FACS-purified BM CD34+ HSPCs from
untreated staging negative lymphoma patients (control samples)
using small interfering RNA (siRNA) (Supplementary Fig. 8a).
LTBR knockdown significantly increased the expression of
genes related to proliferation, such as CCND1, but reduced
Fig. 5 Treatment of Ltbr−/− mice with 5-FU leads to increased HSC cell cycle activity and reduced long-term repopulation. a, b Quantitative RT-PCR
analysis of Ltbr (a) and Light (b) in BM LSKs from naive (black) and 5-FU-treated (red) BL/6 mice 8 days after treatment (for Ltbr: n= 3, for Light: n= 6).
c Fold change of LTβR MFI on HSCs from 5-FU-treated BL/6 (red, n= 7) vs. naive BL/6 mice (black, n= 3). d Total BM cell numbers of BL/6 (gray) and
Ltbr−/− mice (black) 8 days post 5-FU injection (BL/6 n= 20, Ltbr−/− n= 21). e Total numbers of BM LSK subpopulations in 5-FU-treated BL/6 (black)
and Ltbr−/− mice (red), n= 3. f Left: representative FACS profiles of cell cycle analysis of BM LSKs. Right: Percentage of BL/6 and Ltbr−/− LSKs in each cell
cycle phase, blue: G0, white: G1, black: S–G2–M. Data represent one out of two independent experiments; LSKs were pooled for analysis from BL/6 n= 3
and Ltbr−/− n= 5 mice. g Percentages of FACS-purified LSKs from 5-FU-treated BL/6 and Ltbr−/− mice in symmetric (SD, black) or asymmetric division
(AD, red). Data represent one out of two independent experiments, LSK numbers n= 73 (BL/6) and n= 85 (Ltbr−/−). h Fold change of CFU capacity of
FACS-purified BL/6 (black) and Ltbr−/− (red) LSKs in serial re-plating experiments, pooled data from two independent experiments are shown (BL/6 n=
5, Ltbr−/− n= 7). i Ratio of IκBα protein expression and its phosphorylation level of BM LT/ST-HSCs from naive BL/6 (black) and Ltbr−/− mice (red). Data
were pooled from two independent experiments (BL/6 n= 5 mice, Ltbr−/− n= 4 mice). j Ratio of IκBα protein expression and its phosphorylation level of
BM LT/ST-HSCs (Lin−sca−1+CD48−CD150+) from BL/6 and Ltbr−/− mice 8 days post treatment with 5-FU, n= 2 mice were pooled for each data point.
One out of two independent experiments is shown. k Experimental setup of BM reconstitution after 5-FU treatment. l Percentages of Ly5.1 (black) and
Ltbr−/− BM donor cells (red) of recipients 6 weeks post transplantation, one out of two independent experiments (n= 10). Unless otherwise stated, data
are presented as mean ± SEM, *P < 0.05, **P < 0.01, ****P < 0.0001 (two-tailed t test). a: p= 0.0058; b: p < 0.0001; c: p= 0.0092; d: 0.0039; e: p= 0.030;
f: 0.025; g: p= 0.042; h: 1st p= 0.031, 3rd p= 0.025; i: p= 0.55; j: p= 0.047; l: p < 0.0001.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21317-x ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:1065 | https://doi.org/10.1038/s41467-021-21317-x | www.nature.com/naturecommunications 9
stemness-related gene such asMSI2 (Fig. 7b). In addition, CD34+
BM cells treated with siRNA for 24 h formed significantly fewer
colonies in methylcellulose and lost the capacity to form colonies
in serial re-platings, indicating that the knockdown of LTBR
reduced the number of functional HSCs (Fig. 7c).
To analyze the role of LIGHT/LTβR signaling in activated
hematopoiesis, we isolated CD34+ HSPCs from PB of patients that
have been treated with cyclophosphamide mobilization che-
motherapy and granulocyte colony-stimulating factor (G-CSF).
Interestingly, LTβR and LIGHT expression were increased in G-
CSF-mobilized CD34+ HSPCs compared to control BM CD34+
HSPCs (Fig. 7d). LTBR knockdown in G-CSF-mobilized CD34+
HSPCs reduced colony-forming unit (CFU) capacity in the first,
second, and third plating in methylcellulose. By contrast, LIGHT
siRNA treatment resulted in similar numbers of colonies in the first
plating, but significantly fewer colonies after re-plating (Fig. 7e). As
expected, siRNA treatment did only transiently downregulate
LTβR and LIGHT with reconstituted expression after the first
plating (Supplementary Fig. 8d). This indicates that transient
silencing of LTβR or LIGHT leads to differentiation in the first
plating with fewer HSCs capable of self-renewing in the second and
third re-plating. LTBR and LIGHT knockdown significantly
reduced the expression of the stemness-related gene MSI2 in G-
CSF-mobilized HSPCs (Fig. 7f). Importantly, the expression of
MSI2 positively correlated with the expression of LTBR and LIGHT
after knockdown (Supplementary Fig. 8e, f). To analyze the
expression of LTBR, LTA, LTB, and LIGHT in CD34+ CML stem/
progenitor cells, we took advantage of a public available microarray
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dataset (GEO: GSE11675)47. While LTB was similarly expressed in
normal and in CML CD34+ cells, LIGHT and LTBR expression
was clearly increased in CML samples (Fig. 8a). In accordance,
FACS analysis of CD34+ HSPCs from CML patients revealed a
significantly higher LIGHT expression and a trend to a higher
expression of LTβR than in control CD34+ HSPCs (Fig. 8b). LTBR
knockdown in CD34+ CML cells resulted in more colonies in the
first plating in methylcellulose but fewer colonies in the second re-
plating (Fig. 8c and Supplementary Fig. 8g). Importantly, knock-
down of LTBR reduced the expression of MSI2, CTNNB1, and
TNIK, indicating reduced stemness (Fig. 8d).
LIGHT knockdown in CML CD34+ HSPCs resulted in a
reduced CFU capacity after re-plating (Fig. 8e and Supplementary
Fig. 8h). Collectively, these data indicate that LIGHT/LTβR
signaling contributes to the maintenance and self-renewal of
human hematopoietic and CML stem/progenitor cells.
Discussion
In response to an increased demand of blood cells, HSPCs are
activated to enter cell cycling, proliferation, differentiation, and
migration48. This activation is regulated by paracrine signals from
Fig. 6 LTβR expression of LSCs promotes CML progression. a Schematic for CML induction. b Ltbr−/− mRNA expression in naive BL/6 LSKs (black) and
LSCs (red, Lin−GFP+c-kit+sca1+, n= 3). c LTβR expression on BL/6 LSCs. d LightmRNA expression of naive BL/6 LSKs (black) and BL/6 LSCs (red, n= 3).
e BCR/ABL1-GFP+ granulocytes/μl in blood from BL/6 (black, n= 12) and Ltbr−/− CML mice (red, n= 13). One out of two independent experiments is
shown. f Kaplan–Meier survival curves of BL/6 (n= 7) and Ltbr−/− CML mice (n= 11, dashed line: predetermined endpoint of the experiment). g Spleen
weight of BL/6 (black, n= 4) and Ltbr−/− CML mice (red, n= 7). h–j LSC (h), LT-LSC, ST-LSC (i), and leukemic MPPs (j) cell numbers in BM of BL/6 and
Ltbr−/− mice. Data are shown as one out of three independent experiments. k Schematic of secondary CML transplantation with BM cells or LSCs.
l, m Kaplan–Meier survival curves for whole CML BM cells (l, BL/6 n= 4, Ltbr−/− n= 7) and LSCs (m, BL/6 n= 8, Ltbr−/− n= 7). n Percentage of LT-HSC,
ST-HSC, and MPPs from BL/6 and Ltbr−/− mice in G0 (gray), G1 (red), and G2–M–S (black). Data are pooled from two independent experiments (n= 6).
o Percentages of BL/6 and Ltbr−/− LSCs in symmetric (SD, black) or asymmetric division (AD, red), n= 140 cells (BL/6) and n= 230 cells (Ltbr−/−) were
examined in two independent experiments. Data are shown as mean ± SEM. p BCR/ABL1-GFP+ granulocytes/μl in blood from BL/6 (black, n= 6) and
Light−/− CML mice (red, n= 8). One out of two independent experiments is shown. q Spleen weight of BL/6 (black, n= 3) and Light−/− CML mice (red,
n= 4). r–t LSC (r), LT-LSC, ST-LSC (s), and leukemic MPPs (t) cell numbers in BM of BL/6 (n= 3) and Light−/− CML mice (n= 4). Data are shown as
mean ± SEM. Statistics: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (two-tailed t test: b, d, e, g, h–j, n–p, q–t), two-tailed log-rank test (f, l, m),
b: p= 0.0001; d: p < 0.0001; e: p= 0.0001; f: p= 0.0002; g: p= 0.038; h: p= 0.036; i: LT-LSC p= 0.0011; ST-LSC p= 0.0095; j MPP1 p= 0.049, MPP2
p= 0.04; l: p= 0.028; m: p= 0.0196; n: G0 p= 0.014, G1 p= 0.044; o: SD/AD p= 0.0003; p: p= 0.021; q: p= 0.048; r: p= 0.043; s: LT-LSC p= 0.024,
ST-LSC p= 0.048; t: MPP1 p= 0.012, MPP2 p= 0.048.
Fig. 7 LTβR signaling in human HSPCs. a mRNA expression intensity of LTBR and LIGHT in CD34+ cells from 27 healthy donors, analyzed in a publicly
available microarray dataset (GSE32719). b Fold change of relative mRNA expression of indicated genes in HSPCs (CD45intLin−CD34+) from control
samples, transfected with siLTBR (red) relative to HSPCs treated with siCTRL (black), n= 4, pooled for analysis from three independent experiments.
c Fold-change CFU and re-plating of siLTBR- or siCTRL-transfected BM HSPCs (n= 4, pooled for analysis from two independent experiments, shown as
grand mean). d MFI (stain/isotype) of LTβR and LIGHT in BM HSPCs from control samples (black, n= 6) and G-CSF-mobilized PB HSPCs (red, n= 3).
Data from five independent experiments were pooled for analysis. e Fold-change CFU and re-plating of PB HSPCs from G-CSF-treated patients, transfected
with indicated siRNA (n= 4). Data are pooled for analysis from two independent experiments, shown as grand mean. f Fold change of MSI2 mRNA in
HSPCs from G-CSF patients, transfected with siLTBR (red) or siLIGHT (red) relative to HSPCs treated with siCTRL (black) (n= 4, pooled data for analysis
from two independent experiments). Data are presented as mean ± SEM. Statistics: *P < 0.05, **P < 0.01, ***P > 0.001 (two-tailed t test: b–d, and one-way
ANOVA: e, f). b: CCND1 p= 0.018, MSI2 p= 0.043; c: 1st p= 0.0007, 2nd p= 0.0028; d: LTβR p= 0.0007, LIGHT p= 0.030; e: 1st p= 0.04, 2nd
p < 0.0001, 3rd p < 0.0001; f: CTRL vs. siLTBR p= 0.035, CTRL vs. siLIGHT p= 0.029. n.s. Not significant.
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the HSC niche cells including ECs and BM MSCs and from
immune cells of the BM microenvironment6,48. For example, type
I and type II IFNs, G-CSF, and LPS are important activators of
the hematopoiesis in response to increased demand10. In addi-
tion, HSCs sense pathogen-associated molecular patterns during
infection mainly via TLRs and respond with proliferation and
myeloid differentiation49. Danger signals such as TLR signaling
have been shown to induce the autocrine production of hema-
topoietic cytokines in HSPC50. However, primitive HSCs cannot
be activated to proliferate indefinitely since this will lead to
exhaustion of HSCs and loss of LT hematopoiesis51. Therefore,
signaling pathways that regulate HSCs quiescence and cell fate are
crucial for the maintenance of the HSC pool. More than 200
genes have been identified to regulate HSC function52. They are
mainly involved in the regulation of cell cycling, Pten/Akt, and
Wnt pathway53–55. In addition, external cues maintain HSC
quiescence and self-renewal.
Different TNFRs have been implicated in the regulation of
hematopoiesis. TNF-α is a major regulator of demand-adapted
hematopoiesis via signaling through the p55 TNFR 1α56. CD40L
stimulates human cord blood HSPC proliferation and myeloid
differentiation57. In addition, CD70-expressing immune cells
regulate HSPC function and differentiation during infection via
CD27 signaling16,17. CD27, CD40, and LTβR signal via TRAFs 2
and 5, which activate multiple signaling pathways, including the
NF-κB pathway58–60. Our GSEA and a conformational analysis of
the phosphorylation status of IκBα revealed that LIGHT/LTβR
preferentially signals via the canonical NF-κB pathway. Impor-
tantly, the NF-κB pathway has been documented before as a
central regulator of HSC maintenance and homeostasis61.
In addition, CD27 signaling contributes to the maintenance
and expansion of LSCs via TRAF2/TNIK signaling and Wnt
pathway activation18. CD27 and LTβR signaling is mainly regu-
lated by the expression of its respective ligands. The CD27 ligand
CD70 is only expressed on lymphocytes and subsets of dendritic
cells upon activation62. However, permanent CD70 expression on
LSCs allows cell-autonomous CD27 signaling and expansion of
LSCs63. Similarly, LIGHT is expressed mainly on immune cells
upon activation64,65. Here, we show that HSPCs express LIGHT
and that its expression is upregulated upon activation. Interest-
ingly, LTβR is also expressed at higher levels on activated HSCs.
Our in vitro coculture experiments and competitive BM trans-
plant models using Light−/− and control LSKs indicated that
LTβR and LIGHT act in cis in HSCs and this interaction is crucial
for the regulation of self-renewal. In accordance with our findings
in HSCs, soluble LIGHT added to Light−/− CML LSCs did not
rescue colony formation capacity.
LIGHT interacts with three different receptors (HVEM, LTβR,
and decoy receptor 3), two of which are expressed on HSPCs66.
HVEM signaling in murine HSPCs has been shown to induce
myeloid differentiation in response to treatment with LIGHT
in vitro and in vivo66. Here we show that signaling via LIGHT/
LTβR maintained the pool of HSCs and LSCs. Importantly, the
phenotype of Light and Ltbr single KO HSCs was similar to Light/
Ltbr double KO HSCs after treatment with 5-FU, excluding a
major contribution of other receptors in the maintenance of
quiescence. As many other members of the TNF superfamily (e.g.,
TNF-α, Fas-L), LIGHT can act in a soluble or transmembrane
form. Importantly, soluble and transmembrane isoforms of TNF
superfamily members, including LIGHT, cause different effects
on various cell types67–69. We now document that neither soluble
LIGHT protein nor transmembrane LIGHT expressed by another
cell, did rescue the phenotype of Light−/− HSCs, indicating that
cell-autonomous LIGHT/LTβR signaling is responsible for the
observed effects.
LIGHT/LTβR signaling maintains stemness by reducing cell
proliferation and favoring symmetric over asymmetric cell divi-
sion. We analyzed the cell division pattern in most experiments
Fig. 8 LTβR signaling in CD34+ HSPCs from CML patients. a Heatmap analysis for LTBR, LIGHT, and LTB gene expression (log 2 fold differences) in PB
CD34+ Lin− cells from CML patients (red) and healthy donors (blue) of a publicly available dataset (GEO: GSE11675). b MFI of LTβR and LIGHT in BM
HSPCs (black, n= 6) and BM HSPCs from CML patients (red, n= 3). Data are pooled for analysis from five independent experiments. c Fold change CFU
and re-plating of CML HSPCs, transfected with siLTBR vs. siCTRL (n= 4, one sample (Pat 4/5) was used as pooled cells from two CML patients. Data are
pooled for analysis from two independent experiments and shown as grand mean. d Fold change of mRNA expression of indicated genes in siLTBR (red)-
transfected CML HSPCs, relative to siCTRL (black)-treated CML HSPCs (n= 4, data are pooled for analysis from two independent experiments. e Fold-
change CFU and re-platings of siLIGHT (red)-transfected CML HSPCs, relative to siCTRL (black). Cells were pooled from n= 2 CML patients. Data are
presented as mean ± SEM. Statistics: *P < 0.05 (two-tailed t test: b, c). b: LTβR, p= 0.07, LIGHT, p= 0.030; c: 1st, p= 0.018, 2nd, p= 0.029.
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by defining dividing cells and analyzing Numb distribution
according to the cleavage furrow. This analysis has been used by
many groups before63,70,71, but does not allow to precisely define
the axis of cell division. Importantly, the inclusion of an α-tubulin
staining confirmed an increased AD in Ltbr−/− HSPCs, sug-
gesting that LTβR signaling regulates the cell division pattern.
Many molecular pathways that regulate stemness and differ-
entiation also regulate apoptosis and vice versa72. In the present
study, we documented a reduced apoptosis rate in Ltbr−/− HSCs
that further contributes to the initial cell expansion of more
differentiated cells.
It has been shown before that an increase of asymmetric cell
division leads to differentiation and exhaustion of stem
cells12,73,74. This is reflected in an increase in colony formation
capacity in first platings and in an improved engraftment after
transplantation into first recipient mice, a process that is medi-
ated by both HSCs and progenitors32. The exhaustion of func-
tional HSCs leads then to a reduced engraftment in second and
third re-platings or re-transplantations.
The absence of LTβR signaling induced an upregulation of
genes involved in cell cycling and proliferation such as Cdk4 and
Cdk6. These cyclin-dependent kinases are known to complex with
cyclin D1 to regulate G1/S transition and the exit of HSCs from
quiescence75,76. Accordingly, Ltbr−/− HSCs showed a positive
correlation with the signature of positive regulation of G1−S
transition in GSEA analysis. Similarly, knockdown of LTBR in
human CD34+ HSPCs increased the expression of genes involved
in cell cycling while reducing genes associated with stemness.
Functional analysis of HSCs confirmed a reduced proliferation of
LIGHT/LTβR-competent stem cells, especially of the most pri-
mitive LT-HSCs. Moreover, we identified a similar role for LTβR
in the maintenance and expansion of CML stem cells. Ltbr- and
Light-knockout in LSCs reduced the number of leukemia HSPCs
in the BM and prolonged survival in a murine CML model.
Importantly, mouse and human CML cells overexpress LTBR and
LIGHT when compared to normal HSPCs. Knockdown of LTBR
in human CML HSPCs resulted in the downregulation of stem-
ness- and Wnt-related genes, such as MSI2, TNIK, and CTNNB1
and a reduced number of LSCs that form colonies in methylcel-
lulose. Since LSCs are resistant to chemotherapy and probably
also TKIs, targeting pathways that regulate and maintain LSCs
will be crucial to improve the treatment of leukemia77,78.
Importantly, LTβR deficiency did not affect steady-state hema-
topoiesis but did only regulate HSC quiescence and cell fate in
demand-adapted hematopoiesis. Thus, targeting the LIGHT/
LTβR pathway may offer a novel strategy to induce differentiation
and to eliminate LSCs.
Methods
Animals. BL/6 and Ly5.1 mice were purchased from Charles River. Ltbr−/− mice
were kindly provided by Prof. A. Aguzzi (Institute of Neuropathology, University
Hospital of Zurich, Switzerland; Futterer et al.22) and Light−/− mice by S. Scheu
(University Hospital of Düsseldorf, Germany). KO strains are homozygote mutant
mice, generated by intragenic deletions22,23. Intercrosses were validated by geno-
typing PCR and subsequently used for animal husbandry. Light−/− mice on Ly5.1
background were referred to as Ly5.1/Light−/− mice. Offspring mice from
Ly5.1×BL/6 breeding are used as recipient mice (referred to as Ly5.1/Ly5.2).
C57BL/6-Tg(UBC-GFP)30Scha/J mice were kindly provided by Dr. Mario Bonalli
(LASC, University of Zurich, Switzerland)79. Mice aged 6–13 weeks were used for
experiments. Animal experiments were approved by the local experimental animal
committee of the Canton of Bern and performed according to Swiss laws for
animal protection.
BM and blood samples from patients. BM samples from untreated staging
negative lymphoma patients, who were considered normal by a surgical pathologist
and a hematologist, were used as control samples. HSPCs were isolated from
apheresis samples of patients that have been treated with chemotherapy and G-
CSF. PB samples and BM aspirates from untreated CML patients were taken at
diagnosis. Patient samples were collected at the University Hospital of Bern after
written informed consent. Patient characteristics are listed in Supplementary
Tables 1–3. Analysis of samples was approved by the local ethical committee of the
Canton of Bern (KEK122/14).
Isolation of BM cells and lineage depletion. Mice were sacrificed; femurs, tibiae,
humeri, and the spine were crushed in phosphate-buffered saline (PBS). The BM
suspension was filtered through a 40-µm cell strainer. Subsequently, red blood cell
lysis was performed and cells were washed twice with PBS. Lineage depletion was
performed with MACS separation according to the manufacturer’s protocol.
Briefly, BM cells were stained with biotinylated antibodies (all BioLegend, San
Diego, USA) against red cell precursors (αTer119), B cells (αCD19), T cells
(αCD3ε), myeloid cells (αGr1), and α-biotin MicroBeads using LS columns
(Miltenyi Biotec, Bergisch Gladbach, Germany).
Isolation of BM niche cells. BM MSCs, ECs, and osteoblasts were isolated
according to Schepers et al.80. Briefly, bones were cleaned, crushed, and digested
with collagenase and DNase. Isolated cells were stained with αCD31−FITC
(clone:390) αCD51-APC (clone:RMV-7) αLy-6A/E-PerCP-Cy5.5 (clone:D7, all
BioLegend, San Diego, USA) and Streptavidin-V500 (BD Bioscience, Eysins, Swit-
zerland) and hematopoietic cells were excluded using anti-lineage antibodies
(αTer119, αCD19, αCD3ε and αGr1, αCD45 (clone:30F11)). BM niche cells were
characterized using the following surface markers: EC, CD45−CD31+sca1+; MSC,
CD45−Lin−CD31−sca1+CD51+; and osteoblasts, CD45−Lin−CD31−sca1−CD51+.
Homing assay. Ly5.1 and Ltbr−/− LSKs were FACS purified and 26,000 to 54,000
LSKs were injected at a ratio of 1:1 into lethally irradiated Ly5.1/Ly5.2 recipients.
Thirteen hours post transplantation the frequency of LSKs homed to the BM cells
was analyzed by FACS. The frequency of Lin−CD45.1+ and Lin−CD45.2+ cells
was calculated as the percentage of transplanted LSKs.
Treatment with 5-FU. BL/6, Ly5.1, and Ltbr−/− mice were injected intraper-
itoneally with 150 mg/kg 5-FU (Sigma). Eight to 9 days postinjection, BM cells
from Ly5.1 and Ltbr−/− mice were analyzed or injected at a ratio of 1:1 into lethally
irradiated Ly5.1/Ly5.2 recipients (2 × 6.5 Gy with 4-h interval, Gammacell 40
exactor, Best Theratronics, Ottawa, Canada).
Generation of chimeric mice. A total of 15,000–20,000 LSKs from Ly5.1, Ltbr−/−,
or Light−/− mice were injected intravenously at a ratio of 1:1 into lethally irradiated
Ly5.1/Ly5.2 or Ly5.1/Light−/− recipient mice. Serial re-transplantation experiments
were performed 12–18 weeks after primary transplantation. Ly5.1 and Ltbr−/−
LSKs from chimeras were FACS purified and injected intravenously (i.v.) at a ratio
of 1:1 into lethally irradiated Ly5.1/Ly5.2 recipient mice. If re-transplantation was
done with <5000 LSKs (third, fourth transplantation) rescue BM cells were given.
CML mouse model. CML was induced in mice45. Briefly, FACS-purified LSKs
were plated in RPMI medium, supplemented with 10% fetal calf serum (FCS), 1%
glutamine, 1% penicillin/streptomycin, 20 ng/ml thrombopoietin, 100 ng/ml SCF
overnight, and subsequently transduced by spin infection with BCR-ABL1-GFP
retrovirus. CML was induced by i.v. injection of 30,000 transduced LSKs into
nonirradiated recipient mice (BL/6 in BL/6: BL/6 CML; Ltbr−/− in BL/6: Ltbr−/−
CML; Light−/− in BL/6: Light−/− CML). Blood counts were analyzed using a Vet
abc Animal Blood Counter (Medical Solution GmbH, Bassersdorf, Switzerland).
Mice were analyzed at days 18–20 after CML induction. For secondary trans-
plantations, 5 × 106 BM cells or 20,000 FACS-purified LSCs from primary CML
mice (18–20 days after primary transplantation) were injected i.v. into secondary
immunocompetent recipients.
Cell cycle analysis. Ki67 staining was performed with Foxp3/Transcription Factor
Staining Buffer Set (eBioscience, San Diego, USA) according to the manufacturer’s
protocol. In addition, cells were stained with DAPI (Merck, Darmstadt, Germany)
and analyzed by FACS. BrdU incorporation was determined according to the
manufacturer’s protocol (BD Pharmingen BrdU Flow Kits, San Jose, USA).
ImageStream analysis. Numb/α-tubulin (Numb: ab4147, Tubulin: ab7291,
Abcam, Cambridge, UK) staining in FACS-purified LSKs or LT/ST-HSCs from
chimeric mice, 5-FU-treated BL/6 and Ltbr−/− mice (8 days after treatment) or
CML mice was performed as follows: cells were fixed with 4% paraformaldehyde,
followed by permeabilization with 1× wash buffer (Dako wash, Agilent Technolo-
gies, California, USA) and blocking with 10% normal goat serum (Invitrogen,
California, USA) in Dako wash. After overnight incubation at 4 °C with the primary
rabbit α-Numb antibody or tubulin in Dako diluent, cells were incubated with the
secondary antibody (donkey-anti-goat, ab175474; goat-anti-mouse, ab150115) for
1 h at room temperature63. DAPI was used to stain for DNA. Asymmetric cell
division was determined by an increase in Numb intensity of 1.8-fold in one of the
daughter cells11. Cells were acquired using an ImageStreamX MkII imaging flow
cytometer (Merck, Darmstadt, Germany). Cells were analyzed using INSPIRE and
IDEAS Software63.
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Colony-forming cell assays. FACS-purified BM LSKs (600–1 × 103 naive LSKs; 1 ×
104 5-FU-treated Lin−sca1+) were plated in MethoCult (STEMCELL Technologies,
Cambridge, USA) supplemented with 15% FCS, 20% BIT (50mg/ml bovine
serum albumin in Iscove’s modified Dulbecco’s medium), 1.44 U/ml rh-insulin and
250 ng/ml human holo-transferrin, 100 µM 2-mercaptoethanol, 100 U/ml penicillin,
100 µg/ml streptomycin, 2 mM L-glutamine, 50 ng/ml SCF (rmSCF-1), 10 ng/ml
interleukin-3 (rmIL-3), 10 ng/ml interleukin-6 (rhIL-6), and 50 ng/ml fms-related
tyrosine kinase 3 ligand (rmFLTL-3). Re-plating was performed with 10,000 cells per
dish. For CFU assays of human HSPCs, we plated 1000 CD45intLin−CD34+ BM
cells into methylcellulose. Colonies were enumerated after 7–14 days in culture
(≥30 cells/colony) on a DMIL inverted microscope (Leica, Wetzlar, Germany)
Flow cytometry and cell sorting. Cells were stained in PBS with 5% FCS with the
following antibodies for 30 min at 4 °C: αCD117-APC-Cy7 (clone:2B8), αCD48-
PE-Cy7 (clone:HM48-1), αCD150-APC (clone:TC1512F12.2), αLy-6A/E-PerCP-
Cy5.5, -APC (clone:D7, eBioscience, San Diego, USA), αCD16/CD32-PE-Cy7
(clone:93), αCD34-eFluor-450 (clone:RAM34, eBioscience, San Diego, USA),
αCD135-PE, -biotin (clone:A2F10, Novus, Littleton, USA), αCD127-FITC (clone:
A7R34), αCD45.1-PerCP-Cy5.5 (clone:A20), αLTβR-PE (clone:ebio3C8,
eBioscience, San Diego, USA), αLy-6C-PerCP-Cy5.5 (clone:HK1.4), αCD11b-PE-
Cy7, αCD8a-FITC, -APC, FITC (clone:53-6.7), αCD4 (clone:GK1.5), αCD90.1-
APC (clone:OX-7), αCD90.2-APC (clone:30-H12), Annexin-V-Pacific-Blue, -Alexa
Fluor 647, PE, αLy-6G-Pacific-Blue, αCD45.2-Alexa Fluor 700 (clone:104), Ki67-
PE (clone:16A8), rat IgG2a,κ-PE (clone:RTK2758), αCD45-PerCP-Cy5.5, -PE-Cy7,
-APC (clone:30F11). Human HSPCs were stained with αCD90-PeCP-Cy5.5 (clo-
ne:5E10), αCD34-APC (clone:561), αLTβR-PE (clone:31G4D8), αCD38−APC
(clone:HIT2), mouse-IgG2b,κ (clone:MPC-11), αCD2-biotin (clone:RPA2.10),
αCD3Ɛ-biotin (clone:OKT3), αCD14-biotin (clone:HCD14), αCD16-biotin (clo-
ne:3G8), αCD19-biotin (clone:HIB19), αCD56-biotin (clone:HCD56), αCD235a-
biotin (clone:HIR2), αCD45-Pacific-Blue (clone:2D1), Streptavidin-V500 (all from
BioLegend, San Diego, USA). For intracellular staining of NF-κB members, cells
were surface stained, followed by 4% paraformaldehyde fixation and permeabili-
zation via ice-cold methanol, according to the manufacturer’s protocol. Following
primary antibodies were used: phospho-IκBα (Ser32) (clone:14D4), IκBα
(clone:44D4); secondary antibody: anti-rabbit IgG (H+ L), F(ab′)2 Fragment-
Alexa Fluor 647 (all from Cell Signaling Technology Inc., Massachusetts, USA).
FACS was performed on a LSR Fortessa cell analyzer or LSRII Flow cytometer
(both BD Bioscience, San Jose, USA). Cell sorting was done using a BD FACSARIA
III (BD Bioscience, San Jose, USA). Data analysis was performed with Kaluza Flow
analysis software (Beckman Coulter, Krefeld, Germany) or FlowJo software
(Treestar, Oregon, USA).
RNA isolation and quantitative RT-PCR. RNA was isolated according to the
manufacturer’s protocol (NucleoSpin RNA XS, Macherey-Nagel, PA, USA) and the
expression of genes was analyzed using SYBR Green 2× PCR Master Mix (Roche,
NY, USA) on a 7500 real-time PCR System (AB Biosystems, CA, USA). Actin or
Gapdh genes were used for normalization of the gene expression. The sequences of
primers are listed in Supplementary Table 4.
High-throughput transcriptome sequencing (RNA-seq). Total RNA was
extracted from FACS-purified Ltbr−/− and Ly5.1 HSCs (Lin−Annexin-V−sca1+c-
kit+CD150+CD48−) from chimeric mice using the RNeasy Micro Kit (Qiagen AG,
Switzerland) according to the manufacturer’s instructions. Total RNA was quality
checked on the Bioanalyzer instrument (Agilent Technologies, USA) using the
RNA 6000 Pico Chip (Agilent, USA) and quantified by Fluorometry using the
QuantiFluor RNA System (Promega, USA).
Library preparation (average library size: 313 ± 3 bp) was performed from 20 ng
total RNA using the TruSeq Stranded mRNA Library Prep Kit High Throughput
(Cat# RS-122-2103, Illumina, San Diego, CA, USA) and quality (average
concentration: 6.7 ± 1.8 nmol/L) was analyzed on the Fragment Analyzer
(Advanced Analytical, Ames, IA, USA, High Sensitivity NGS Fragment Analysis
Kit, Cat# DNF-473, Advanced Analytical). Samples were pooled, quantified,
adjusted to equal molarity (1.4 pM, QuantiFluor ONE dsDNA System, Cat# E4871,
Promega, Madison, WI, USA), and used for clustering on the NextSeq 500
instrument (Illumina). Samples were sequenced in single reads with 76 bases using
the NextSeq 500 High Output Kit 75 cycles (Illumina, Cat# FC-404-1005). Primary
data analysis was performed with the Illumina RTA version 2.4.11 and Basecalling
Version bcl2fastq-2.20.0.422. An average per sample of 62 ± 3.6 million reads was
obtained.
RNA-seq data analysis to access differentially expressed genes. The RNA-seq
data were assembled by SeqMan NGen software v.16 and analyzed using ArrayStar
software v.16 (DNASTAR, USA). The level of gene expression was assessed using
regularized logarithm values from Bioconductor. After statistical analysis, genes
with a significant difference in their expression at false discovery rate p < 0.05 and
fold differences ≥1.5 were selected. Data were clustered using standard Euclidean’s
method based on the average linkage and heatmaps were generated according to
the standard normal distribution of the values (Supplementary Dataset 1).
Gene set enrichment analysis. GSEA was performed using GSEA software v.3.0
(Broad Institute). Enrichment analysis was assessed for all pathway-related genes
acquired from PathCards database (pathcards.genecards.org).
Transfection of human HSPCs with siRNA. FACS-purified BM CD34+ HSPCs
from patients undergoing a diagnostic BM aspirate that was considered normal by
a hematologist and an independent surgical pathologist (control donor) and
CD34+ HPSCs from the blood of G-CSF-treated patients were cultured in Stem-
Span SFEM medium in combination with StemSpan CC100 (STEMCELL Tech-
nologies) and transfected with control siRNA (siCTRL), LTbR targeting siRNA
(siLTBR), or LIGHT targeting siRNA (siLIGHT) (Santa Cruz Biotechnology,
Heidelberg, Germany) using TransIT-X2 (Mirus Bio Muttenz, Switzerland)
according to the manufacturer’s protocol. Genes were analyzed 24 h post trans-
fection unless otherwise stated.
Statistical analysis. Statistics were calculated using Prism 8.0 (Graph Prism
Software, USA). Data were analyzed using one-way analysis of variance and
Tukey’s or Dunnett’s multiple comparison test or Student’s t test. Survival curves
were analyzed using a log-rank (Mantel–Cox) test. Data are displayed as mean ±
SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All relevant data are available upon request from the authors. All transcriptomic
data compiled for this study have been deposited in NCBI GEO under the accession
code: GSE141206. Expression data were derived from a public repository for microarray
data (GEO) and are available under accession number GSE32719 (ref. 46) and
GSE11675 (ref. 47).
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